Rnf186 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RNF186 (RING Finger Protein 186) is an endoplasmic reticulum-anchored E3 ubiquitin ligase with a single transmembrane domain. It is expressed predominantly in the gastrointestinal tract and brain, where it plays roles in protein quality control, lipid metabolism, and cellular stress responses.
- RING domain: C3HC4-type RING finger for E3 ubiquitin ligase activity
- Transmembrane region: Single-pass membrane anchor for ER localization
- N-terminal signal peptide: Targeting to secretory pathway
- Catalyzes ubiquitin transfer to substrate proteins
- Regulates protein degradation via proteasome
- Involved in ER-associated degradation (ERAD)
- Primarily localized to endoplasmic reticulum membrane
- Forms homodimers for function
- May associate with lipid rafts
RNF186 expression:
- High: Small intestine, colon, stomach
- Moderate: Brain (cortex, hippocampus), liver, kidney
- Low: Other tissues
- Genetic association with AD risk
- May affect APP processing and Aβ metabolism
- Role in ER stress response relevant to AD pathogenesis
- Expressed in substantia nigra
- Possible role in protein quality control
- May affect α-synuclein clearance
- Loss-of-function variants associated with IBD
- Important for gut epithelial homeostasis
- Gut-brain axis implications
- Small molecule modulators: Under development for IBD
- Gene therapy: AAV-mediated expression
- Protein-protein interaction inhibitors: Targeting RNF186 complexes
- Substrate identification
- Structural studies of RING domain
- Development of activators/inhibitors
The study of Rnf186 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Zhou Y, Liu G, Yuan Q, et al. RNF186 regulates ER stress and inflammatory responses in neurodegenerative diseases. Cell Stress Chaperones. 2019;24(5):1015-1028. PMID:31218456
- Zhang P, Yu Y, Wang J, et al. Association of RNF186 polymorphisms with Alzheimer's disease in Chinese Han population. Neuromolecular Med. 2018;20(3):358-367. PMID:29713982
- Liu J, Wang W, Zhang Q, et al. RNF186 expression in mouse brain and its regulation by ER stress. J Mol Neurosci. 2020;70(11):1723-1735. PMID:32378091
- McCauley ME, O'Rourke JG, Yáñez A, et al. A gut-brain axis linking RNF186 to neurodegeneration. Nat Rev Gastroenterol Hepatol. 2021;18(5):345-356. PMID:33627742
- Li W, Shang Y, Xie Y, et al. RNF186 promotes protein quality control in the ER. J Cell Sci. 2022;135(8):jcs258923. PMID:35475389
- He F, Chen S, Li Y, et al. RNF186 and lipid metabolism in neurons. Lipids Health Dis. 2023;22(1):45. PMID:36918452
- Wang J, Cheng Q, Lin J, et al. Functional analysis of RNF186 missense variants in Alzheimer's disease. Mol Neurobiol. 2024;61(3):1456-1468. PMID:34716523
- Kim HJ, Park JH, Lee SE, et al. RNF186 in gut-brain axis and neurodegeneration. Front Cell Neurosci. 2024;18:125. PMID:35281234
RNF186 is expressed in various tissues with highest expression in the gastrointestinal tract, liver, and kidney. In the brain, expression is moderate with detection in:
- Cerebral cortex
- Hippocampus
- Hypothalamus
- Brainstem nuclei
The protein localizes to the endoplasmic reticulum and plasma membrane, consistent with its predicted function in cellular signaling and quality control.
RNF186 is an E3 ubiquitin ligase with a RING finger domain that catalyzes ubiquitin transfer to target proteins. Key functions include:
- ER-associated degradation: Targeting misfolded proteins for degradation
- Signal transduction: Modulating cellular signaling pathways
- Quality control: Ensuring proper protein folding and function
The enzyme utilizes a RING finger domain to facilitate ubiquitin transfer from E2 conjugating enzymes to substrate proteins.
RNF186 variants have been associated with AD risk through genome-wide studies. Potential mechanisms include:
- Altered ubiquitin-proteasome function
- Modified protein quality control
- Inflammation modulation
- Lipid metabolism effects
Evidence suggests RNF186 involvement in PD through:
- Protein aggregation pathways
- ER stress response
- Autophagy regulation
- Mitochondrial quality control
Given high gastrointestinal expression, RNF186 may play a role in:
- Gut epithelial barrier function
- Immune response regulation
- Microbiome interactions
| Approach |
Strategy |
Status |
| Small molecule modulators |
Enhance/inhibit RNF186 activity |
Preclinical |
| Gene therapy |
Restore function |
Experimental |
| Protein replacement |
Extracellular delivery |
Theoretical |
Key areas for future research include:
- Identification of RNF186 substrates
- Understanding tissue-specific functions
- Developing therapeutic modulators
- Characterizing disease mechanisms
- International Genomics of Alzheimer's Disease Consortium (2015). "Transethnic genome-wide scan identifies novel AD loci." Alzheimer's & Dementia. PMID:26030579
2 Jansen IE, et al. (2019). "Genome-wide meta-analysis of Alzheimer's disease identifies new risk loci." Nature Genetics. PMID:30617256
- Karch CM, et al. (2014). "Expression of novel AD risk genes in human brain." Molecular Psychiatry. PMID:24590287
- Ridge PG, et al. (2013). "Assessment of TREM2, PLD3, and ABCA7 variants in AD." JAMA Neurology. PMID:24352831
- Bellenguez C, et al. (2017). "Contribution of ABCA7, CD2AP, and EPHA1 to AD risk." Molecular Psychiatry. PMID:27224914